Oxaliplatin-based chemotherapy

Phase 3Small molecule

Amgen

Oxaliplatin-based chemotherapy is one of 150 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

149

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Intestinal CancerActive, not recruiting

Colorectal CancerActive, not recruiting

NeuropathyActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Intestinal CancerPhase 3

Active, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

NeuropathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Oxaliplatin-based chemotherapy

Amgen

Phase 3

1 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

PEG-Intron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Neuropathy

NCT07167446

Clinical

Trials by Indication[1]

Lymphoma1 trial

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT01300156·37 enrolled

Colorectal Cancer1 trial

PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

Completed· Amgen logo

Amgen·Phase 3·NCT00115765·1,053 enrolled

Neuropathy1 trial

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

Recruiting·FFox Chase Cancer Center·Phase 1·NCT07167446·30 enrolled

Neuroendocrine Tumors1 trial

MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents

Completed·HHospices Civils de Lyon·N/A·NCT03217097·116 enrolled

Intestinal Cancer1 trial

Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer

Completed·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT02486198·145 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Oxaliplatin-based chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxaliplatin-based chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxaliplatin-based chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Amgen

Oxaliplatin-based chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Lymphoma1 trial

Colorectal Cancer1 trial

Neuropathy1 trial

Neuroendocrine Tumors1 trial

Intestinal Cancer1 trial

References

Drug Info

Quick Facts

Related News